Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Connor

Showing results (1-10 of 106) with videos related to

Pageof 11
Sort By:
British Journal of Pharmacology|January 13, 2009
Allopurinol for pain relief: more than just crystal clearance?Mark Connor
British Journal of Pharmacology|April 3, 2012
What would 5-HT do? Regional diversity of 5-HT(1) receptor modulation of primary afferent neurotransmissionMark Connor
British Journal of Pharmacology|April 17, 2009
Shadows across mu-Star? Constitutively active mu-opioid receptors revisitedMark Connor
British Journal of Pharmacology|January 13, 2006
Has the sun set on kappa3-opioid receptors?Mark Connor, Ian Kitchen
British Journal of Pharmacology|February 18, 2014
Cellular signalling of non-synonymous single-nucleotide polymorphisms of the human μ-opioid receptor (OPRM1)Alisa Knapman, Mark Connor
Methods in Molecular Biology (Clifton, N.J.)|September 22, 2021
Employing the Operational Model to Measure System-Independent OTR EfficacyKiyan Afzali, Mark Connor
Methods in Enzymology|November 2, 2010
Constitutively active μ-opioid receptorsMark Connor, John Traynor
Methods in Molecular Biology (Clifton, N.J.)|October 9, 2014
Fluorescence-based, high-throughput assays for μ-opioid receptor activation using a membrane potential-sensitive dyeAlisa Knapman, Mark Connor
Current Opinion in Pharmacology|January 22, 2005
Opioids: cellular mechanisms of tolerance and physical dependenceChris P Bailey, Mark Connor
Recent Patents on CNS Drug Discovery|January 29, 2008
TRPV1 antagonists as a potential treatment for hyperalgesiaLouise A Roberts, Mark Connor
Pageof 11

Showing results (1-10 of 106) with videos related to

Sort By:
Pageof 11
British Journal of Pharmacology|January 13, 2009
Allopurinol for pain relief: more than just crystal clearance?Mark Connor
British Journal of Pharmacology|April 3, 2012
What would 5-HT do? Regional diversity of 5-HT(1) receptor modulation of primary afferent neurotransmissionMark Connor
British Journal of Pharmacology|April 17, 2009
Shadows across mu-Star? Constitutively active mu-opioid receptors revisitedMark Connor
British Journal of Pharmacology|January 13, 2006
Has the sun set on kappa3-opioid receptors?Mark Connor, Ian Kitchen
British Journal of Pharmacology|February 18, 2014
Cellular signalling of non-synonymous single-nucleotide polymorphisms of the human μ-opioid receptor (OPRM1)Alisa Knapman, Mark Connor
Methods in Molecular Biology (Clifton, N.J.)|September 22, 2021
Employing the Operational Model to Measure System-Independent OTR EfficacyKiyan Afzali, Mark Connor
Methods in Enzymology|November 2, 2010
Constitutively active μ-opioid receptorsMark Connor, John Traynor
Methods in Molecular Biology (Clifton, N.J.)|October 9, 2014
Fluorescence-based, high-throughput assays for μ-opioid receptor activation using a membrane potential-sensitive dyeAlisa Knapman, Mark Connor
Current Opinion in Pharmacology|January 22, 2005
Opioids: cellular mechanisms of tolerance and physical dependenceChris P Bailey, Mark Connor
Recent Patents on CNS Drug Discovery|January 29, 2008
TRPV1 antagonists as a potential treatment for hyperalgesiaLouise A Roberts, Mark Connor
Pageof 11